ATOSSA THERAPEUTICS
Atossa Therapeutics is a clinical-stage biopharmaceutical company focusing on breast cancer and other breast conditions. They offer treatment for pre-cancerous breast conditions and early-stage breast cancer.
ATOSSA THERAPEUTICS
Industry:
Biotechnology Clinical Trials Genetics Health Care Therapeutics
Founded:
2009-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.atossatherapeutics.com
Total Employee:
51+
Status:
Active
Contact:
+1 206 588 0256
Total Funding:
57.8 M USD
Technology used in webpage:
Domain Not Resolving SPF Amazon Google Google Cloud Google Apps For Business Pound Sterling GoDaddy DNS Amazon Virginia Region Japanese Yen
Similar Organizations
Blue Belt Technologies
Blue Belt Technologies is a medical device company that focuses on technology and capabilities of surgical instrumentation.
Echo Therapeutics
Echo Therapeutics develops the Symphony tCGM System, a novel, non-invasive (needle-free) glucose monitoring system for diabetes patients.
Encoded Therapeutics
Encoded Therapeutics is a Harnessing the regulatory genome to create next-generation molecular therapies.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Gurnet Point Capital
Gurnet Point Capital is a private equity firm that invests in de-risked life sciences companies
Human Longevity
Human Longevity is a genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived.
Instadiagnostics
Instadiagnostics Inc., is developing a rapid, quantitative, point-of-care (POC) diagnostic platform.
Telcare
Telcare develops machine-2-machine cellular technology that wirelessly connects patients and physicians to cure chronic illnesses.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Aspire Capital Partners LLC
Aspire Capital Partners LLC investment in Post-IPO Equity - Atossa Therapeutics
Keiretsu Forum Northwest
Keiretsu Forum Northwest investment in Venture Round - Atossa Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-07-02 | Atossa Therapeutics appoints Heather Rees as chief financial officer |
Official Site Inspections
http://www.atossatherapeutics.com Semrush global rank: 4.35 M Semrush visits lastest month: 2.28 K
- Host name: hwsrv-245137.hostwindsdns.com
- IP address: 23.254.209.175
- Location: Seattle United States
- Latitude: 47.4902
- Longitude: -122.3004
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98168
More informations about "Atossa Therapeutics"
Atossa Genetics Announces Corporate Name Change ... - Atossa โฆ
Jan 6, 2020 For more information, please visit www.atossatherapeutics.com. Forward-Looking Statements. ... Non-Profit organization, Abilities Inc. Dr. Per Hall. MD, PHD. Dr. Hall is widely โฆSee details»
Atossa Therapeutics, Inc. | LinkedIn
Atossa Therapeutics, Inc. Biotechnology Seattle, WA 5,060 followers Clinical-stage biopharmaceutical company developing novel, proprietary therapeutics for breast cancer and โฆSee details»
Atossa Therapeutics, Inc. (ATOS) - Yahoo Finance Canada
See the company profile for Atossa Therapeutics, Inc. (ATOS) including business summary, industry/sector information, number of employees, business summary, corporate governance, โฆSee details»
Atossa Therapeutics - Crunchbase Company Profile & Funding
Atossa Therapeutics reported its year-end 2023 and first quarter 2024 financial results, indicating financial growth. The company also completed the enrollment of an 80mg pharmacokinetic run โฆSee details»
Atossa Therapeutics (ATOS) Company Profile & Description
Nov 8, 2012 Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other โฆSee details»
Atossa Therapeutics - 2025 Company Profile - Tracxn
2 days ago Atossa Therapeutics - Developer of drugs for treating breast cancer. Public Company. Raised a total funding of $6.74M over 4 rounds. Founded by Steven Quay in the โฆSee details»
News Releases - Atossa Therapeutics
Jan 23, 2025 Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, โฆSee details»
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 ...
Mar 20, 2025 The webcast will be available at the investor relations section of the Company's website at atossatherapeutics.com. Alternatively, to access the conference call by telephone, โฆSee details»
Investor Presentation - investors.atossatherapeutics.com
Novel SERM, De-risked, Strong IP 6 โข (Z)-endoxifen: โข Competitive inhibitor of ERฮฑ and represses ERฮฑ transcriptional activity โข 100-fold more potent in anti-estrogen activity compared to other โฆSee details»
Atossa Therapeutics Announces Clinical Progress
Apr 2, 2020 For more information, please visit www.atossatherapeutics.com. Forward-Looking Statements. ... Non-Profit organization, Abilities Inc. Dr. Per Hall. MD, PHD. Dr. Hall is widely โฆSee details»
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 ...
Mar 20, 2025 For more information, visit atossatherapeutics.com. Contact Michael Parks , VP Investor and Public Relations 484-356-7105 [email protected] Source: Atossa โฆSee details»
Atossa Therapeutics Advances Product Development Programs โฆ
Jul 8, 2020 Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a โฆSee details»
Atossa Therapeutics Announces Support of New Breast Cancer โฆ
May 7, 2024 For more information, please visit www.atossatherapeutics.com. Contact: Eric Van Zanten VP, Investor and Public Relations 610-529-6219 [email protected]. โฆSee details»
Atossa Therapeutics Announces Full Year 2024 Financial Results โฆ
2 days ago Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time โฆSee details»
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial โฆ
Nov 4, 2024 Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on โฆSee details»
Atossa Therapeutics Announces Second Quarter 2022 Financial โฆ
Aug 8, 2022 Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious diseases with a current โฆSee details»
Atossa Therapeutics to Release Final Data from Phase 2
Jun 7, 2021 Tribe Public LLC is a San Francisco, CA-based organization that hosts complimentary worldwide webinar & meeting events in the U.S. Tribe's events focus on issues โฆSee details»
Atossa Therapeutics, Inc. Receives Authorization from FDA
Oct 24, 2022 InClin Inc., a full-service Contract Research Organization, has been contracted to execute this study. This study is a multicenter (approximately 25 sites) study in United States โฆSee details»
Atossa Therapeutics Applauds U.S. Surgeon Generalโs Advisory ...
SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (โAtossaโ or the โCompanyโ), a clinical-stage biopharmaceutical company dedicated to the โฆSee details»
Atossa Therapeutics Announces Third Quarter 2022 Financial โฆ
SEATTLE, Nov. 07, 2022 โ Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on โฆSee details»